Showing 3 results for Pacemaker
Dr Ali Kazemi Saeed, Dr Ahmad Yamini-Sharif, Dr Mahnaz Alam-Zadeh, Dr Maria Reiesi-Dehkordi, Dr Gholamreza Davoodi,
Volume 9, Issue 2 (6-2006)
Abstract
Background: Permanent pacemakers are applied to treat some 2nd and 3rd degree AV blocks. Previous studies have shown the hemodynamic changes that may occur after pacemaker implantation. In this study, we have evaluated these hemodynamic changes from a different view point, with measurement of urinary sodium and blood pressure. Materials and Methods: This is a before and after clinical trial study in which 30 patients, who were hospitalized for permanent pacemaker implantation for the first time in Tehran heart center during 3 years, including 12 women (mean age 62.92 years) and 18 men (mean age 60.07 years), were tested for urinary specific gravity and sodium, blood pressure, blood sodium and potassium, before and after pacemaker implantation. Paired sample T test and Chi Square test were used for statistical analysis. Results: Systolic blood pressure was 136.5 mmHg and 120.6 mmHg before and after pacemaker implantation, (P<0.001). Also, after pacemaker implantation, urinary sodium rose from 83.45 meq/L to 106.61 meq/L (p=0.018). Conclusion: This study is consistent with previous studies, which showed hemodynamic changes after permanent pacemaker implantation including decrease in blood pressure and elevation of serum neuropeptides.
Valiollah Khadir Sharabiany, Saeed Oraii,
Volume 12, Issue 4 (2-2010)
Abstract
Background: Since cardiac surgeons have not kept up with advancements in pacing technology, there has been a tendency to limit the implantation of pacemakers by surgeons. This study compares two eras of pacing therapy including pacemaker implantation by cardiac surgeons and pacemaker set-up by a group of cardiologists in Shahid Rajaee Hospital in Tehran. Materials and Methods: In this cross-sectional study, we compared the existing data from all pacemaker implantations in the first half of 1999 (surgical era, era 1) to that of the first half of 2001 (cardiologists era, era 2). Results: During era 1, a total 114 pacemakers (46.5% male, mean age 63.3 ±18.4) and during era 2, 299 pacemakers (63.9% male, mean age 63.9±18.2) had been implanted. Indications for implantation were nearly similar, with AV block as the most common reason in 21.9% and 19.1% of implantations in eras 1 and 2, respectively. Single chamber pacemakers comprised 86% of implantations during era 1 compared to 54% during era 2 (p<0.01). The mean duration of admission was 18 days during era 1 while it was 10 days during era 2. Pacemaker malfunctions were detected following 7.9% of implantations in era 1 compared to 0.3% of cases in era 2 (p<0.01). Re-do procedures were performed after 2.7% of implantations during era 1 in comparison to 0.3% during era 2 (p<0.01). Conclusion: Pacemaker implantation was performed better by a coordinated pacemaker service run by cardiologist trained in pacemaker implantation.
Valiollah Khadir Srabiany,
Volume 17, Issue 10 (1-2015)
Abstract
Background: Statins are the most effective drugs for treatment of elevated level of cholesterol. In addition, they exhibit other effects unrelated to their lipid lowering effects (pleiotropic actions). In recent years, experimental and clinical evidences demonstrate that statins exert anti-inflammatory properties. The aim of this study is evaluation of association Atorvastatin in reduction of peak threshold in patients with permanent pacemaker.
Materials and Methods: In these clinical trial 64 eligible patients that candidate for permanent pacemaker enrolled. After in formed consent patients randomly divided to two equal groups. In first group atorvastatin 20 mg/daily administered orally for six weeks and second group considered as control. Peak atrial and ventricular threshold were measured in beginning of study and in sixth week. The data collected and analyzed and p<0.05 considered statistically meaning full.
Results: from 32 subjects in Atorvastatin group 17 (53.12%) were male and 15(46.87%) were female. Average mean age in Atorvastatin and control group was 72.43±17.27 and 68.59 ±10.98 years, respectively. No difference showed in atrial and ventricular threshold in two groups at beginning of study. At end of study atrial threshold in atorvastatin and control group were 0.55±0.23 and 0.45±0.19 respectively (p=0.4) and ventricular threshold in atorvastatin and and control group were 0.73±0.23 (p=0.4).
Conclusion: There is no association between atorvastatin therapy and reduction in pacemaker peak arterial and ventricular threshold.
